Merck Animal Health teams with Cambridge Technologies to provide autogenous vaccines to US poultry industry

Merck Animal Health has entered into an agreement with Cambridge Technologies, an independent custom vaccine company based in Worthington, Minnesota, to sell and market its innovative autogenous poultry vaccines in the US.

Cambridge Technologies uses cutting-edge molecular diagnostic and manufacturing techniques to develop custom vaccine solutions to help veterinarians and poultry producers manage emerging disease challenges. Through this agreement, Cambridge will contribute its production expertise and distribution, while Merck Animal Health will provide its expansive customer reach.

“For this agreement, we are linking together the reach of our Merck Animal Health sales and marketing teams to offer our customers the diagnostic expertise of Cambridge research scientists to provide flock-specific biologics with customized options,” said Jim Tate, executive director, Integrated Livestock business in North America for Merck Animal Health.

Cambridge Technologies vaccines are formulated and produced at its USDA-licensed, 37,000-square-foot manufacturing facility featuring state-of-the-art fermentation suites.

“The Cambridge team has extensive experience in diagnostics, R&D, quality control, technical support, regulatory affairs and commercial and custom vaccine production,” said Jon Mahlberg, chief operating officer for Cambridge Technologies.

“Our vaccines are scientifically designed to meet the customer’s specific needs, and we are excited to combine our capabilities with those of Merck Animal Health to meet the unique needs of poultry customers.”

Production of the first vaccine batches is currently being planned. To learn more about these custom vaccine products, contact your Merck Animal Health sales or technical services representative.

 

Editor’s notes:

Merck Animal Health, known as MSD Animal Health outside the US and Canada, is a division of Merck & Co., Inc.

Content on Modern Poultry’s Industry Insights pages is provided and/or commissioned by our sponsors, who assume full responsibility for its accuracy and compliance.

 

 

Posted on: April 23, 2024

post it

Merck Animal Health has entered into an agreement with Cambridge Technologies, an independent custom vaccine company based in Worthington, Minnesota, to sell and market its innovative autogenous poultry vaccines in the US.

#poultryhealth #poultrytech

RELATED CONTENT

Modern Poultry is pleased to host
this editorial page on behalf of

Merck Animal Health